Displaying drugs 576 - 600 of 1505 in total
INS018_055
Investigational
AP-001
Investigational
Ivarmacitinib
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
LY374571
Experimental
APD-209
Investigational
Brogidirsen
Brogidirsen is under investigation in clinical trial NCT05996003 (NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)).
Investigational
IKT-001Pro
Investigational
MPT-0L055
Investigational
BPR-0L075
Investigational
Rhein
Rhein is an anthraquinone metabolite of rheinanthrone and senna glycoside is present in many medicinal plants including Rheum palmatum, Cassia tora, Polygonum multiflorum, and Aloe barbadensis . It is known to have hepatoprotective, nephroprotective, anti-cancer, anti-inflammatory, and several other protective effects.
Experimental
Stamulumab
MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Investigational
BMN-044
Experimental
Withdrawn
BMX-001 free base
Investigational
TAK-075 Free base
Investigational
BMN-045
Experimental
Withdrawn
Tetulomab tetraxetan Lu-177
Betalutin has been used in trials studying the treatment of Non-Hodgkin Lymphoma and Relapsed, Diffuse Large B-cell Lymphoma.
Investigational
U-0126
U-0126 is a direct inhibitor of the mitogen-activated protein-kinase kinase family members, MEK-1 and MEK-2.
Investigational
M-032
Investigational
MZE001
Investigational
ALMB-0168
ALMB-0168 is a humanized connexin 43 (Cx43) monoclonal antibody being investigated for osteosarcoma.
Investigational
Edobacomab
Investigational
Verzistobart
Verzistobart is under investigation in clinical trial NCT06056895 (Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma).
Investigational
PVX-410 component XBP1 SP367-375 (YLFPQLISV)
Investigational
MBP-091
MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).
Investigational
Displaying drugs 576 - 600 of 1505 in total